Abiopharma

🔍 Malady Kyle (Director)

Company: DEXCOM INC (DXCM)

Report Date: 2025-09-05

Detailed Transactions and Holdings:

• Sold 667 shares of Common Stock at $80.86 per share (Direct)
  Date: 2025-09-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 22,667.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: On June 6, 2025, Mr. Malady adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Malady. The shares set forth above were sold pursuant to the 10b5-1 Plan.
• F2: Included in this number are 5,192 unvested restricted stock units which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.
• REMARKS: Exhibit 24 - Power of Attorney